This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Aortitis in diseases classified elsewhere달리 분류된 질환에서의 대동맥염 (대동맥염)

Contents and key points
ItemDetails
A. Classification codesICD-10: I79.1 (aortitis in diseases classified elsewhere) | Special Copayment Reduction: V192 (special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsSecondary aortitis, secondary aortitis, Secondary aortitis, Aortitis due to systemic disease
C. Adult onsetManifests during the course of an underlying systemic disease (syphilis, IgG4-related disease, rheumatic diseases, etc.) and is diagnosed mainly in middle-aged and older adults.
1. HistoryStarting from 19th-century descriptions of syphilitic aortitis, a classification system with IgG4-related and rheumatic causes was established in the late 20th century
2. CausesSyphilis (Treponema pallidum), IgG4-related disease, giant cell arteritis, ankylosing spondylitis, rheumatoid arthritis, etc.
3. GeneticsGenetic predispositions related to the underlying disease, such as HLA-DR and IL1R1 gene variants, contribute to vulnerability to the disease
4. General epidemiologyVaries with the prevalence of the underlying disease; IgG4-related aortitis is more frequent in men aged 60 and over
5. PathophysiologyInflammatory cell infiltration in the aortic wall → destruction of vessel wall structure → aneurysm formation or stenosis
6. SymptomsNonspecific systemic symptoms such as chest pain, back pain, fever, fatigue, and loss or reduction of pulses
7. SignsAortic regurgitation, aortic bruit, asymmetric upper limb blood pressure, palpable aortic aneurysm, etc.
8. ScreeningESR, CRP, serum IgG4, syphilis serology (VDRL/TPHA), ANA, ANCA panel
9. DiagnosisCT angiography, PET-CT, transesophageal echocardiography, pathological confirmation by tissue biopsy
10. TreatmentTreatment specific to the underlying disease (antibiotics, glucocorticoids, immunosuppressants), surgical correction of aneurysms
11. PrognosisGood prognosis with early diagnosis and treatment of the underlying disease; high mortality with aortic aneurysm rupture
12. PreventionPrevention and early treatment of syphilis, aggressive management of systemic inflammatory diseases, regular aortic imaging follow-up
13. ReferencesUnraveling the complexity of IgG4-related aortitis and periarteritis: from pathogenesis to clinical practice … and 9 other papers

1. History

The history of aortitis began with the syphilis epidemics of the 19th century. In 1856 Ernst Rindfleisch first described in detail the characteristic inflammatory changes of the aortic wall at autopsy of syphilis patients, and clinicians of the era, including William Osler, subsequently confirmed that syphilitic aortitis is the core lesion of cardiovascular syphilis. From the late 19th to the early 20th century, syphilitic aortitis was one of the main causes of cardiovascular death in Western developed countries, and in the era before penicillin was introduced it was recorded as the most common cause of aortic regurgitation and aortic aneurysm.

With the widespread use of penicillin in the mid-20th century, the frequency of syphilitic aortitis fell sharply, and researchers' attention accordingly shifted to aortic involvement by autoimmune and systemic inflammatory diseases. In the 1960s–70s, associations of rheumatoid arthritis, ankylosing spondylitis and systemic lupus erythematosus with aortitis were reported one after another. In particular, the occurrence of aortic regurgitation in ankylosing spondylitis was first systematically reported by Toone (1959) and others, and aortic lesions were subsequently identified in various seronegative spondyloarthropathies.

The concept of IgG4-related disease (IgG4-RD) was established after Hamano et al. reported elevated serum IgG4 in autoimmune pancreatitis in 2001, and around 2009–2012 it became clear that IgG4-RD can involve the aorta and large vessels. As a result, the ICD-10 code category "aortitis in diseases classified elsewhere (I79.1)" came to comprehensively cover secondary aortic inflammation due to various underlying diseases, such as syphilis, autoimmune diseases, IgG4-RD and giant cell arteritis. In the 2020s, advances in PET-CT and high-resolution vascular MRI have made it possible to detect even clinically silent aortic inflammation early, raising the possibility that the actual prevalence of secondary aortitis is higher than previous estimates.


2. Causes

The I79.1 code applies when a separate causative disease precedes as the primary diagnosis and the aorta is secondarily involved in the course of that disease. The most classic cause is syphilis (Treponema pallidum), in which endarteritis obliterans, occurring mainly in tertiary syphilis, involves the nutrient vessels of the aortic wall (vasa vasorum) and causes chronic inflammation of the media and adventitia. Even today, syphilitic aortitis cannot be excluded from the differential diagnosis in countries reporting a resurgence of syphilis.

IgG4-related aortitis/periaortitis is one of the causes drawing the most attention recently and is known to account for about 6–9% of all aortic inflammation. It is characterized by tissue infiltration of IgG4-positive plasma cells and fibrosis and mainly involves the abdominal aorta and iliac arteries. Giant cell arteritis (GCA) is a large vessel vasculitis that occurs most often in women aged 50 and over and can cause aortic aneurysm and aortic dissection. In seronegative spondyloarthropathies, including ankylosing spondylitis, aortic root inflammation and aortic regurgitation also occur, with lesions tending to concentrate just above the aortic valve.

In addition, rheumatoid arthritis, Behçet's disease, relapsing polychondritis, inflammatory bowel disease and systemic lupus erythematosus have been reported as underlying diseases of secondary aortic inflammation. Rarely, infectious aortitis caused by Mycobacterium tuberculosis, Salmonella, staphylococci and others may also fall within this category, but in that case a separate infection code should be applied first.


3. Genetics

The genetic background of aortitis in the I79.1 category reflects the genetic predisposition of each underlying disease. For IgG4-related aortitis, recent genome-wide association studies (GWAS) have shown that variants in the IL1R1 (interleukin-1 receptor type 1) gene are significantly associated with IgG4-related periaortitis and retroperitoneal fibrosis. The HLA region is also related to susceptibility to IgG4-RD as a whole, and an association with the HLA-DRB1*04 allele has been confirmed in some cohorts.

Regarding aortic involvement in giant cell arteritis, the HLA-DRB1*04 and HLA-DRB1*01 alleles are known to be the strongest genetic risk factors. These HLA variants are presumed to induce abnormal activation of CD4+ T cells, amplifying Th1 and Th17 immune responses within the vessel wall. Aortic lesions in ankylosing spondylitis are strongly associated with HLA-B27, and the frequency of aortic regurgitation is significantly higher especially in B27-positive patients.

Although infectious causes dominate in syphilitic aortitis, studies have found that genes involved in regulating the host immune response (e.g., TNF-α promoter polymorphisms, MBL gene variants) may influence whether the disease progresses to tertiary syphilis. Overall, genetic research in secondary aortitis is proceeding in a form dependent on each underlying disease, and identification of independent genetic factors specific to aortic involvement remains a task for the future.


4. General epidemiology

The exact incidence and prevalence of secondary aortitis corresponding to I79.1 are difficult to estimate in aggregate because of the diversity of underlying diseases. Giant cell arteritis (GCA) has an incidence of 15–30 per 100,000 in people aged 50 and over, and aortic lesions are reported in about 18–40% of these. IgG4-related aortitis occurs most often in men in their 60s–70s, and reports are increasing among Asian patients, centered on Japan. IgG4-related aortitis is estimated to account for about 4–9% of all surgical aortic aneurysm specimens.

Syphilitic aortitis has become rare in developed countries, but it cannot be ignored because syphilis infections are rising again worldwide. According to a 2022 WHO report, new syphilis infections worldwide reach about 7 million per year, and about 25–40% of untreated secondary syphilis carries a risk of progression to the tertiary stage. In Korea, based on Health Insurance Review & Assessment Service (HIRA) data, the number of Special Copayment Reduction registrations for aorta-related rare cardiovascular diseases is increasing every year, and among these, secondary aortitis is classified as a major item together with Takayasu arteritis.

The prevalence of aortic regurgitation in ankylosing spondylitis reaches about 3–10% in patients with disease duration of more than 10 years, and it is more frequent in HLA-B27-positive patients and those with peripheral arthritis. Overall, the diagnosis of secondary aortitis is becoming more frequent as awareness of immune-mediated vascular diseases grows in aging societies.


5. Pathophysiology

The pathogenesis of secondary aortitis differs with the characteristics of the underlying disease, but the common core mechanism is an immune-mediated inflammatory response within the aortic wall. The aortic wall has a three-layer structure of intima, media and adventitia, and the pattern of involvement of each layer differs by cause.

In syphilitic aortitis, Treponema pallidum reaches the vasa vasorum of the aortic adventitia hematogenously and causes endarteritis obliterans. As a result, the smooth muscle cells and elastic fibers of the media undergo ischemic necrosis, and chronic granulomatous inflammation progresses through infiltration of spleen-specific T cells and macrophages. Damage to the media eventually leads to loss of aortic elasticity, causing ascending aortic aneurysm and aortic regurgitation.

In IgG4-related aortitis, numerous IgG4-positive plasma cells infiltrate the adventitia and media through a cooperative response of CD4+ T cells and B cells, accompanied by storiform fibrosis mediated by TGF-β and IL-13. In giant cell arteritis, activation of dendritic cells recruits CD4+ Th1 and Th17 cells to the vessel wall, and activated macrophages and multinucleated giant cells form granulomas around the internal elastic lamina. In this process, intimal proliferation from VEGF (vascular endothelial growth factor) overexpression and degradation of the vessel wall by MMPs (matrix metalloproteinases) cause aneurysm formation and stenosis simultaneously.


6. Symptoms

The clinical symptoms of secondary aortitis vary with the activity of the underlying disease and the location and extent of aortic lesions. The most common symptoms are chest pain and back pain, which, being inflammatory in nature, tend to persist at rest and worsen at night. When an aneurysm has formed, an ascending aortic aneurysm can cause retrosternal pain or pain radiating toward the jaw, and a descending thoracic aortic aneurysm is characterized by interscapular pain.

Fever, night sweats, weight loss and generalized fatigue, reflecting a systemic inflammatory state, commonly accompany active aortitis and are prominent especially in giant cell arteritis and IgG4-related disease. When flow disturbance from aortic involvement develops, upper limb blood pressure differences, reduced or absent pulses and intermittent claudication may appear. With accompanying aortic regurgitation, dyspnea, nocturnal cough, palpitations and heart failure symptoms appear; this is a complication requiring particular attention in aortic lesions related to ankylosing spondylitis.

If aneurysm rupture or dissection occurs, it becomes an emergency with sudden, severe chest or abdominal pain, hypotension and signs of shock. Syphilitic aortitis is characterized by aneurysm and aortic regurgitation as the main manifestations without aortic stenosis, and angina from coronary ostial stenosis may accompany it.


7. Signs

On physical examination, the specific signs of secondary aortitis are varied. The aortic regurgitation murmur is a high-pitched decrescendo murmur heard in diastole, best auscultated at the left sternal border in the 3rd–4th intercostal spaces. Aortic regurgitation in syphilitic aortitis is often due to aortic root dilatation rather than a structural abnormality of the valve itself, and this should be considered in surgical correction.

Giant cell arteritis is characterized by temporal artery tenderness and loss of pulsation and scalp tenderness, and a systolic blood pressure difference between the arms (≥10 mmHg) suggests subclavian artery involvement. Upper limb blood pressure differences are found in about 15–20% of patients with giant cell arteritis. In IgG4-related aortitis, the main sign is an abdominal aortic aneurysm felt as a pulsatile mass on abdominal palpation, and hydronephrosis from ureteral obstruction by retroperitoneal fibrosis may accompany it.

In aortic lesions related to ankylosing spondylitis, an aortic regurgitation murmur may be heard along with signs of spondyloarthropathy, such as limited spinal mobility and reduced chest expansion. With progressive heart failure, signs of congestive heart failure such as jugular venous distension, leg edema and crackles are observed. Loss of dullness in Traube's space suggests splenomegaly, which is a useful clue in assessing the activity of the underlying systemic disease.


8. Screening

Screening for secondary aortitis should proceed systematically in patients in whom an underlying systemic disease is suspected or a nonspecific aortic lesion has been found. In basic blood tests, the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are the most sensitive inflammatory markers, and their marked elevation strongly suggests active aortic inflammation. However, ESR and CRP are nonspecific, so further tests for differential diagnosis are essential.

Syphilis serology combines the nonspecific VDRL or RPR test with the specific TPHA/FTA-ABS test. In particular, a high RPR titer with a positive FTA-ABS indicates overt syphilis infection, and following titer changes in relation to treatment history is important. Serum IgG4 concentration is used to screen for IgG4-RD, with 135 mg/dL or higher as the positive cutoff, but its sensitivity is limited at about 60–80%. It should therefore be noted that a normal IgG4 level does not rule out IgG4-related aortitis.

ANA, ANCA, RF, anti-CCP, HLA-B27 tests are needed to screen for lupus, vasculitis, rheumatoid arthritis and ankylosing spondylitis, respectively. A complete blood count (CBC) and chemistry panel (liver function, renal function, uric acid) help evaluate organ involvement by the underlying disease. A 12-lead ECG and chest X-ray are essential for the initial cardiac evaluation, and aortic dilatation or mediastinal widening is an important clue prompting rapid imaging.


9. Diagnosis

Two requirements must be met to confirm I79.1. First, the diagnostic criteria for the underlying disease (syphilis, IgG4-RD, GCA, ankylosing spondylitis, etc.) must be met, and second, aortic inflammation or a structural abnormality must be objectively demonstrated as a manifestation of that disease.

The standard of imaging diagnosis is CT angiography (CTA), which can rapidly evaluate aortic wall thickening (ring-shaped contrast enhancement ≥3 mm), the extent of aneurysms and branch vessel involvement. 18F-FDG PET-CT captures active inflammation of the aortic wall very sensitively (sensitivity 80–90%) and is also useful for evaluating treatment response and monitoring for relapse. However, FDG uptake can also be increased in atherosclerosis, so care is needed in interpretation. Transesophageal echocardiography (TEE) is excellent for high-resolution evaluation of the aortic root, ascending aorta and aortic regurgitation.

Tissue biopsy and pathology are the final means of confirmation; for IgG4-related aortitis, a histological diagnosis requires ≥10 IgG4-positive plasma cells per high-power field (HPF) and an IgG4/IgG ratio ≥40%. Syphilitic aortitis shows nonspecific granulomatous changes and plasma cell infiltration around the vasa vasorum, and direct detection of the organism is difficult. The sensitivity of temporal artery biopsy for giant cell arteritis is 60–70%, so treatment should be started if clinical suspicion is high even when the biopsy is negative.


10. Treatment

In treating secondary aortitis, treatment specific to the underlying disease comes first, together with management of vascular complications. For syphilitic aortitis, the standard antimicrobial treatment is benzathine penicillin G (2.4 million IU intramuscularly, single dose) or, in patients with penicillin allergy, doxycycline (100 mg bid, 28 days). After syphilis treatment the inflammation of aortic lesions subsides, but aneurysms that have already formed do not heal, so surgical or endovascular repair may be needed.

The first-line treatment of IgG4-related aortitis is glucocorticoids, with a standard starting dose of prednisolone 30–40 mg/day, tapered over several weeks according to response. In relapsing or steroid-dependent cases, immunosuppressants such as mycophenolate mofetil, azathioprine and rituximab are added. In giant cell arteritis, high-dose steroids (prednisolone 40–60 mg/day) are standard, and the IL-6 receptor blocker tocilizumab is approved for combination use to prevent relapse and allow steroid tapering.

Indications for surgical treatment of aortic complications are an ascending aortic aneurysm diameter ≥5.5 cm (≥5.0 cm with Marfan syndrome), rapid growth (≥0.5 cm/6 months) and aortic dissection. Endovascular stent placement (EVAR/TEVAR) can be an alternative in patients at high surgical risk, but during active inflammation the risk of postoperative restenosis and infection increases, so it is recommended to perform it after inflammation is controlled where possible. Surgical correction of aortic regurgitation is considered with severe regurgitation or left ventricular dysfunction.


11. Prognosis

The prognosis of secondary aortitis varies greatly with the type of underlying disease, timing of diagnosis, treatment response and presence of aortic complications. When diagnosed early and the underlying disease is appropriately treated, clinical remission of aortic inflammation can be expected, but complete normalization of vascular structure is often difficult. IgG4-related aortitis generally responds well to steroid treatment, but about 30–40% relapse after tapering or discontinuation, so long-term follow-up is needed.

In giant cell arteritis with an accompanying aortic aneurysm, the prognosis is poor, and the risk of death related to aortic complications within 5 years of diagnosis is considerably high. Rupture of an aortic aneurysm is an emergency with mortality reaching 50–90%, and early detection and preventive surgery are key to improving prognosis. In syphilitic aortitis, life expectancy improves after antibiotic treatment, but the risk of rupture of an already formed aneurysm persists.

With severe aortic regurgitation, improvement in heart failure and better long-term survival after valve replacement have been reported. Overall, the standard of long-term prognostic management in secondary aortitis is to control the underlying disease while monitoring changes in aortic diameter with imaging follow-up (CTA or MRA) every six months or once a year.


12. Prevention

Prevention of secondary aortitis focuses on prevention and early treatment of the underlying disease. For syphilis prevention, safe sexual behavior, condom use and regular testing for sexually transmitted infections (STIs) are recommended. In particular, guidelines recommend syphilis serology once or twice a year for people with HIV infection and groups at high risk of STIs. Prompt treatment of secondary syphilis can effectively prevent progression to the tertiary stage and cardiovascular complications.

To prevent aortic complications in autoimmune and systemic inflammatory diseases, early diagnosis of rheumatic diseases and long-term suppression of inflammation are key. The ACR/EULAR recommendations include performing aortic imaging once a year from early after diagnosis in patients with giant cell arteritis to detect aneurysm development early. In patients with ankylosing spondylitis, evidence is accumulating that introducing TNF-α inhibitors effectively lowers systemic inflammation and may reduce the occurrence of aortic complications.

Management of cardiovascular risk factors (hypertension, hyperlipidemia, smoking, diabetes) is also an important supplementary prevention strategy in secondary aortitis. When chronic inflammation and atherosclerosis coexist, they have a synergistic effect on the risk of aortic complications, so statins and antiplatelet agents, smoking cessation and blood pressure control are recommended in combination.


13. References

  1. Della-Torre E, Campochiaro C, Bozzolo EP, et al. Unraveling the complexity of IgG4-related aortitis and periarteritis: from pathogenesis to clinical practice. Frontiers in Immunology. 2025;16:1625456. DOI: 10.3389/fimmu.2025.1625456. PMID: 40442494.

  2. Mizushima I, Yamano S, Inoue D, et al. IgG4 related disease and aortitis: an up-to-date review. Frontiers in Cardiovascular Medicine. 2023;10:1086066. DOI: 10.3389/fcvm.2023.1086066. PMID: 36763458.

  3. Liozon E, Ly KH, Vidal E. Giant cell arteritis and aortitis. Joint Bone Spine. 2018;85(4):421–426. DOI: 10.1016/j.jbspin.2017.09.002. PMID: 28890238.

  4. Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis. Arthritis & Rheumatology. 2022;74(12):1881–1889. DOI: 10.1002/art.42325. PMID: 36350123.

  5. Heggemann F, Hamm K, Arendt CT, et al. Aortitis in the setting of IgG4-related disease: diagnosis, workup, and treatment. Cardiovascular Diagnosis and Therapy. 2020;10(4):1153–1163. DOI: 10.21037/cdt-20-237. PMID: 32968627.

  6. Sato Y, Notohara K, Kojima M, et al. IgG4-related disease: historical overview and pathology. Clinical and Experimental Nephrology. 2010;14(1):1–11. DOI: 10.1007/s10157-009-0244-x. PMID: 19937091.

  7. Bossone E, Eagle KA. Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes. Nature Reviews Cardiology. 2021;18(5):331–348. DOI: 10.1038/s41569-020-00472-6. PMID: 33328581.

  8. Talarico R, Barsotti S, Elefante E, et al. Systemic vasculitides and aortitis: clinical features and treatment. Presse Medicale. 2015;44(6 Pt 2):e221–e228. DOI: 10.1016/j.lpm.2014.11.025. PMID: 25619409.

  9. Stone JH, Zen Y, Deshpande V. IgG4-related disease. New England Journal of Medicine. 2012;366(6):539–551. DOI: 10.1056/NEJMra1104650. PMID: 22316447.

  10. Ohlsson B, Svensson P, Gustafson P, et al. Aortitis: classification, diagnosis, and management. Clinical Cardiology. 2023;46(5):507–517. DOI: 10.1002/clc.24000. PMID: 36847131.